[The role of MRI in measuring the effectivity of disease modifying treatments I]. / Az MRI helye a sclerosis multiplex kezelés hatékonyságának megítélésében I.: mérési markerek.

MRI has a significant role in the diagnosis of multiple sclerosis. The newer and newer treatment options of the disease make it necessary to monitor the effectiveness of the therapy. Besides the clinical signs (clinical relapses and progression), the different MRI parameters can also reflect the disease activity. In our current article we summarize those MRI markers, which best predict the long-term disability, based on the international standards.

[The role of MRI in measuring the effectivity of disease modifying treatments II]. / Az MRI helye a sclerosis multiplex kezelés hatékonyságának megítélésében II.: mérési protokollok.

The paraclinical examinations, principally the MRI have an increasing significance in the diagnosis of multiple sclerosis. However, MRI markers also have a prominent role in monitoring of the disease-course and activity, and also in the planning of possible therapeutic changes. In accordance with previously published international guidelines, in this article we propose a protocol for the monitoring the treatment efficacy in multiple sclerosis. This could be the basis of a consensus based guideline to be implemented in Hungary.

Artefacts on magnetic resonance imaging with Osia®2 bone conduction hearing aid: A cadaver study.

OBJECTIVES: Hearing implants often limit the assessment of magnetic resonance examinations due to susceptibility artefacts. Our aim was to evaluate the impact of artefacts attributed to the Osia®2 implant system in terms of utility in visualizing selected cranial structures. METHODS: A BI300 implant and an OSI200 actuator were implanted into a human cadaver head in the audiologically most favourable position according to the manufacturer's guidelines. Scanning was accomplished using the institutional head and inner ear protocol with a General Electric 1.5 Tesla scanner with retained and removed implant magnet, extended with T1 and T2 weighted sequences with metal-artefact reduction (MAVRIC SL). Image quality was evaluated by three radiologists. RESULTS: The Osia®2 produced significant artefacts in most of the series of standard imaging sequences predominantly on the ipsilateral side of the head. The majority of the artefacts were caused by the implant magnet. Even without removing the magnet, MAVRIC SL improved image quality to such an extent that it became comparable with that after magnet removal. CONCLUSIONS: The standard sequences suffer considerable quality loss due to the artefacts, attributed predominantly to the magnetic component. Metal-artefact reduction sequences are effective in obtaining sufficient-to-good quality images without surgical magnet removal.

Miyazaki Syndrome due to Ventriculoperitoneal Shunt Treatment.

BACKGROUND: The signs and pathomechanism of Miyazaki syndrome is presented through the case of a young female patient. CASE DESCRIPTION: The 33-year-old patient had undergone placement of a ventriculoperitoneal shunt with a pressure-adjustable valve for communicating hydrocephalus years before presenting to our department with the complaints of constant headache and unsteady gait. On the basis of the clinical picture and her history, plain and contrast-enhanced cranial and whole spine magnetic resonance imaging and magnetic resonance angiography examinations were performed, with the scans revealing signs indicative of cerebrospinal fluid hypotension typical of Miyazaki syndrome. CONCLUSION: The article discusses the available literature suggesting the underlying cause in such cases to be the dysfunction of the Starling resistor mechanism due to an improperly adjusted ventriculoperitoneal shunt, which results in excessive cerebrospinal fluid loss accompanied by consequent cerebral venous overflow with vertebral venous engorgement and compressive cervical myelopathy.

Monitoring human herpesvirus-6 in patients with autologous stem cell transplantation.

BACKGROUND/AIM: Due to the increasing number of immunocompromised patients and widely used autologous stem cell transplantation procedures, clinicians have to face with the emergence of infectious diseases. In this setting, we mainly focus our interest on cytomegalovirus (CMV) testing and only in some cases on other herpesviruses (HHV). Herein, we present monitoring of HHV-6 virus re-activation and infection in patients after autologous stem cell transplantation. MATERIALS AND METHODS: One hundred and twenty-one blood and 2 cerebrospinal fluid specimens from 35 patients were tested for the presence of HHV-6 DNA. RESULTS: In 4 patients, a positive HHV-6 signal was detected. In 1 patient, simultaneous detection of CMV and HHV-6 could be observed; however, a low copy number result during CMV testing was obtained. Delayed engraftment or other clinical signs of infection could not be detected in patients with a positive HHV-6 result, except in the case of patient 4 who had limbic encephalitis due to HHV-6 reactivation. CONCLUSION: Because of the possible severe manifestations of HHV-6 infection in immunocompromised patients, screening of HHV-6 infection or reactivation is recommended as part of the routine laboratory procedure.

Stroke in essential thrombocythemia.

BACKGROUND: Our aim was to assess the incidence and the special characteristics of stroke, as a severe complication of patients diagnosed with essential thrombocythemia (ET). METHODS: A retrospective analysis was carried out on 102 patients with ET enrolled and analyzed from the period between 1999 and 2012. Patients with one or more strokes were selected. The characteristics of stroke events, the medication, and the median platelet counts were revised. RESULTS: One or more stroke events were revealed in 11 cases (4 males and 7 females) with a median age of 67 years [range: 45-82 years]. The median platelet count at hematological diagnosis was 658×10(9)/L [range: 514-1157×10(9)/L], while during the time of stroke it was 450×10(9)/L [range: 320-885×10(9)/L]. The median follow-up of the patients with stroke was 60 months [range: 19-127 months]. At the time of the stroke, almost all the patients (8/11 cases, 73%) were already on anti-platelet therapy, alone or in combination with cytoreductive therapy (e.g. hydroxyurea). Brain imaging modalities in most cases demonstrated periventricular and/or subcortical and/or basal ganglia lacunes or confluent chronic white matter ischemic lesions in all cerebral arterial regions. Most patients (9/11; 82%) presented at least two serious conventional vascular risk factors, which may have influenced both the clinical course and the morphologic alterations. No correlation was found between the platelet count and the occurrence of stroke. CONCLUSION: Our findings lead us to suppose that ET may be regarded as a risk factor for stroke (mainly of ischemic, small-vessel type), and the early diagnosis and the personalized management of the patient's global vascular risk in the treatment of ET may promote the prevention of further cerebrovascular events.